DN

Ginkgo Bioworks Holdings Inc. Class A Common Stock Earnings Recaps

DNA Health Care 3 recaps
Next earnings: November 5, 2026 (estimated) · full calendar
Q2 2026 Aug 7, 2026

Shares plunged 9.3% following a steep 48% revenue decline and continued margin pressure, signaling investor disappointment with significant top-line deceleration and ongoing elevated losses despite cost-cutting efforts.

Key takeaways
  • Q2 revenue dropped 48% year-over-year to $20 million, reflecting sharp deceleration in core business.
  • Adjusted EBITDA loss widened to $36 million from $25 million a year ago, indicating margin compression despite reduced operating expenses.
  • Net loss from continuing operations increased to $57 million from $53 million in Q2 2025.
  • Cash burn rose to $45 million in Q2, up from $38 million the prior year, despite restructuring and cost controls.
  • Guidance maintained for 2026 cash burn of $125 million to $150 million, showing cautious outlook without improvement in near-term profitability.
Full recap
Q3 2025 Nov 8, 2025

Ginkgo Bioworks reported a significant reduction in cash burn and reaffirmed its 2025 revenue guidance, despite a challenging environment in the biotechnology sector.

Key takeaways
  • Quarterly cash burn decreased by 75% year-over-year to $28 million, significantly improving the company's cash position with $462 million in cash and no bank debt.
  • Cell Engineering revenue fell 61% year-over-year to $29 million due to a previous noncash revenue spike; adjusted revenue was down only 11% compared to the prior year.
  • Biosecurity revenue reached $9 million with a gross margin of 19%, and segment operating loss improved by 21% from a year prior.
  • The company remains focused on expansion in AI and automation, with plans to deliver autonomous labs at customer sites.
  • Ginkgo reaffirmed its full-year 2025 revenue guidance between $167 million and $187 million, with expectations for Cell Engineering revenue to range from $117 million to $137 million.
Full recap
Q2 2025 Aug 8, 2025

Ginkgo Bioworks reported a significant reduction in cash burn and costs, achieving a $250 million annual run rate savings three months ahead of schedule while guiding for continued revenue growth in 2025.

Key takeaways
  • Cell Engineering revenue increased by 8% year-over-year to $39 million, with a 10% rise in revenue-generating programs.
  • Total adjusted EBITDA improved by 72%, reducing losses to $28 million from $99 million a year ago.
  • Successful restructuring resulted in a 63% decrease in R&D expenses and a 57% drop in G&A expenses.
  • Cash burn was reduced to $38 million, down from $110 million in the same quarter last year, enabling a stronger cash position of $474 million.
  • Full-year revenue guidance for 2025 remains unchanged, with expectations of $167 million to $187 million, reflecting strategic growth initiatives.
Full recap

Go deeper on DNA and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.